Shots:

• Eisai gets the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate- including the CBB for use in healthcare and other markets. The agreement allows the two companies to replicate the advancements that have already been launched in Japan- where Eisai has developed and launched a new digital tool using the CBB- named NouKNOW
• The collaboration is an expansion of an existing agreement signed in 2019- under which Eisai had exclusive development and commercialization rights in Japan for all cognitive function tests including CBB
• Eisai and Cogstate will work together for the development of digital tools for simpler self-checks of cognitive function and diagnostic tool development for HCPs to promote greater awareness of brain performance globally

 ­ Ref: PRNewswire | Image: BioSpectrum Asia